CMV

$3.25M NIH grant to support research in oral manifestations of HIV, including mouth cancer Researchers at the Case Western Reserve University School of Dental Medicine will use a $3.25 million grant from the National Institutes of Health (NIH) to better understand how HIV impacts the human body, from mouth lesions to oral […]

Case Dental gets $3.25M NIH grant to support research in ...

 in News  tagged A5383 / anti-CMV / CMV / CMV and HIV / cmv disease / ELICIT Study / HIV / letermovir by
ACTG launches A5383, clinical trial evaluating potential immunologic benefits of treating asymptomatic CMV in people living with HIV The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the initiation of A5383, a clinical trial evaluating whether the anti- cytomegalovirus (CMV) drug letermovir reduces inflammation when […]

A5383: ELICIT clinical trial of anti-CMV medication letermovir

 in News  tagged A5383 / anti-CMV / CMV / CMV and HIV / cmv disease / ELICIT Study / HIV / letermovir by
Participant Summary Click here for a printable participant summary.   Title: A5355 – Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based anti-Cytomegalovirus (CMV) Vaccine (Triplex®), in Adults with Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART […]

A5355: a clinical trial of an anti-CMV vaccine

 in Clinical Trials / People Living With HIV  tagged CMV / CMV vaccine / cytomegalovirus / HIV research / HIV treatment / HIV treatment study / People Living With HIV / Triplex by